Harrow (HROW) EBT Growth (3y) (2013 - 2026)
Harrow (HROW) EBT Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 21.00% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.19% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 3.60% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -29.91% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 10.08% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 39.40% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 50.36 Mn | -59.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -59.65% |
| Mar 31, 2026 | -58.46% |
| Dec 31, 2025 | 114.40% |
| Sep 30, 2025 | 29.24% |
| Jun 30, 2025 | 41.04% |
| Mar 31, 2025 | -93.92% |
| Dec 31, 2024 | 41.94% |
| Sep 30, 2024 | 20.40% |
| Jun 30, 2024 | -32.91% |
| Mar 31, 2024 | -301.06% |
| Dec 31, 2023 | -118.68% |
| Sep 30, 2023 | -32.59% |
| Jun 30, 2023 | -153.67% |
| Mar 31, 2023 | 18.75% |
| Dec 31, 2022 | -25.97% |
| Sep 30, 2022 | 17.93% |
| Jun 30, 2022 | -36.83% |
| Mar 31, 2022 | -30.36% |
| Dec 31, 2021 | -33.92% |
| Sep 30, 2021 | -49.07% |